Correction: Advances in immunotherapy for triple-negative breast cancer.
作者信息
Liu Yang, Hu Yueting, Xue Jinqi, Li Jingying, Yi Jiang, Bu Jiawen, Zhang Zhenyong, Qiu Peng, Gu Xi
机构信息
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning Province, China.
Department of Health Management, Shengjing Hospital of China Medical University, Shenyang, 110004, Liaoning Province, China.
出版信息
Mol Cancer. 2023 Sep 14;22(1):154. doi: 10.1186/s12943-023-01858-z.
Abstract
摘要
相似文献
1
Correction: Advances in immunotherapy for triple-negative breast cancer.更正：三阴性乳腺癌免疫治疗的进展。
Mol Cancer. 2023 Sep 14;22(1):154. doi: 10.1186/s12943-023-01858-z.
2
Triple-negative breast cancer: recent treatment advances.三阴性乳腺癌：近期治疗进展
F1000Res. 2019 Aug 2;8. doi: 10.12688/f1000research.18888.1. eCollection 2019.
3
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.三阴性乳腺癌的免疫治疗：现存挑战与振奋前景。
Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19.
4
Recent advances in therapeutic strategies for triple-negative breast cancer.三阴性乳腺癌治疗策略的最新进展。
J Hematol Oncol. 2022 Aug 29;15(1):121. doi: 10.1186/s13045-022-01341-0.
5
Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.基于PD-1/PD-L1免疫检查点阻断的转移性三阴性乳腺癌联合免疫疗法
Int Immunopharmacol. 2022 Dec;113(Pt B):109444. doi: 10.1016/j.intimp.2022.109444. Epub 2022 Nov 16.
6
Recent advances in triple negative breast cancer: the immunotherapy era.三阴性乳腺癌的最新进展：免疫治疗时代。
BMC Med. 2019 May 9;17(1):90. doi: 10.1186/s12916-019-1326-5.
7
Top advances of the year: Breast cancer.年度重大进展：乳腺癌。
Cancer. 2023 Jun 15;129(12):1791-1794. doi: 10.1002/cncr.34752. Epub 2023 Apr 4.
8
Triple negative breast cancer: any closer to cracking the code?三阴性乳腺癌：离破解密码更近了吗？
Curr Opin Obstet Gynecol. 2022 Feb 1;34(1):52-55. doi: 10.1097/GCO.0000000000000769.
9
Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer.UFM1 对 PLAC8 的修饰通过影响三阴性乳腺癌中 PD-L1 水平来影响肿瘤增殖和免疫反应。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005668.
10
Advances in immunotherapy for triple-negative breast cancer.三阴性乳腺癌的免疫治疗进展。
Mol Cancer. 2023 Sep 2;22(1):145. doi: 10.1186/s12943-023-01850-7.
引用本文的文献
1
Targeting LINC02544/miR-497-5p/CAPRIN1 axis via exosome-based siRNA to overcome immunotherapy resistance in triple-negative breast cancer.通过基于外泌体的小干扰RNA靶向LINC02544/miR-497-5p/CAPRIN1轴以克服三阴性乳腺癌的免疫治疗耐药性。
Mol Med. 2025 Aug 16;31(1):278. doi: 10.1186/s10020-025-01336-w.
2
Cytoplasmic HMGB1 promotes the activation of JAK2-STAT3 signaling and PD-L1 expression in breast cancer.细胞质中的高迁移率族蛋白B1（HMGB1）促进乳腺癌中JAK2-STAT3信号通路的激活及程序性死亡受体配体1（PD-L1）的表达。
Mol Med. 2025 May 19;31(1):197. doi: 10.1186/s10020-025-01235-0.
3
Studying the Role of Novel Carbon Nano Tubes as a Therapeutic Agent to Treat Triple Negative Breast Cancer (TNBC) - an and Study.研究新型碳纳米管作为治疗三阴性乳腺癌（TNBC）的治疗剂的作用——一项[此处原文“an and Study”表述不完整，无法准确翻译]研究。
J Can Res Updates. 2024;13:37-41. doi: 10.30683/1929-2279.2024.13.06. Epub 2024 Nov 11.
4
Recent Advances in Immunotherapy for Breast Cancer: A Review.乳腺癌免疫治疗的最新进展：综述
Breast Cancer (Dove Med Press). 2024 Aug 27;16:497-516. doi: 10.2147/BCTT.S482504. eCollection 2024.
本文引用的文献
1
Advances in immunotherapy for triple-negative breast cancer.三阴性乳腺癌的免疫治疗进展。
Mol Cancer. 2023 Sep 2;22(1):145. doi: 10.1186/s12943-023-01850-7.
Zotero 插件